Sign in

CIK 0001515673

  • Large accelerated filer

Ultragenyx Pharmaceutical Inc.

Sign in to watch
Ticker
RARE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
272546083
Phone
+1 415-483-8800
Business address
60 LEVERONI COURT, NOVATO, CA, 94949
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$127,561
in 3 filings, $17K under 10b5-1 plans

Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-03-01 Huang Dennis Karl See Remarks Grant or award +22,000 75,703
2023-03-01 Huang Dennis Karl See Remarks Sale −389 $45.65 $18K 75,314
2023-03-01 Huang Dennis Karl See Remarks Returned to the company −10,599 $45.65 $484K 64,715
2023-03-01 Huang Dennis Karl See Remarks Grant or award · Stock Option (Right to Buy) +39,400 39,400
2023-03-01 Pinion John Richard See Remarks Grant or award +2,663 61,929
2023-03-01 Pinion John Richard See Remarks Grant or award +22,000 83,929
2023-03-01 Pinion John Richard See Remarks Sale −3,755 $45.26 $170K 80,174
2023-03-01 Pinion John Richard See Remarks Returned to the company −4,014 $45.65 $183K 76,160
2023-03-01 Pinion John Richard See Remarks Grant or award · 3/1/2023 +39,400 39,400
2023-03-01 KAKKIS EMIL D President & CEO Grant or award +8,716 569,406
2023-03-01 KAKKIS EMIL D President & CEO Grant or award +46,200 615,606
2023-03-01 KAKKIS EMIL D President & CEO Shares withheld for taxes −16,140 $45.65 $737K 599,176
2023-03-01 KAKKIS EMIL D President & CEO Grant or award · Stock Option (Right to Buy) +83,500 83,500
2023-03-01 Harris Erik EVP & Chief Commercial Officer Grant or award +2,663 38,823
2023-03-01 Harris Erik EVP & Chief Commercial Officer Grant or award +22,000 60,823
2023-03-01 Harris Erik EVP & Chief Commercial Officer Sale −3,664 $45.25 $166K 57,344
2023-03-01 Harris Erik EVP & Chief Commercial Officer Grant or award · Stock Option (Right to Buy) +39,400 39,400
2023-02-28 Huizenga Theodore Alan SVP, Chief Accounting Officer Sale −639 $43.40 $28K 15,558
2022-12-30 KAKKIS EMIL D President & CEO Sale −19,582 $45.57 $892K 541,108
2022-12-21 Huizenga Theodore Alan SVP, Chief Accounting Officer Sale −2,031 $43.96 $89K 16,197

Page 14 of 21 · 410 trades